|Bid||4.06 x 900|
|Ask||16.24 x 800|
|Day's range||9.80 - 10.16|
|52-week range||9.47 - 10.71|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
CHICAGO & NEW YORK, May 31, 2022--Cardio Diagnostics, Inc. ("Cardio Diagnostics" or the "Company"), a pioneering precision cardiovascular medicine company, and Mana Capital Acquisition Corp. (Nasdaq: MAAQU; MAAQ; MAAQW; MAAQR) ("Mana"), a special purpose acquisition company ("SPAC"), today announced that they have entered into a definitive business combination agreement that will result in Cardio Diagnostics becoming a publicly listed company.
DOVER, Del., January 12, 2022--Mana Capital Acquisition Corp. (Nasdaq: MAAQU) ("Mana" or the "Company"), today announced that, commencing January 14, 2022, holders of the 6,500,000 units sold in the Company’s initial public offering may elect to separately trade the Company’s common stock, warrants, and rights included in the units. Each unit consists of one share of common stock, one-half of one redeemable warrant, and one right to receive one-seventh (1/7) of one share at the closing of a busi
DOVER, Del., November 26, 2021--Mana Capital Acquisition Corp. (Nasdaq: MAAQU) ("Mana" or the "Company"), a newly incorporated blank check company, today announced the closing of its initial public offering. The offering was priced at $10.00 per unit, resulting in gross proceeds of $62,000,000.